MacAndrews & Forbes

vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. vTv Therapeutics has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company. The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology. vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo. Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification. vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.

Relationship Science (RelSci) is a technology solutions company that helps individuals and organizations leverage their relationships for a competitive business advantage. The RelSci platform provides deep information about over 6 million influential decision makers - who they are and who they know, what you have in common with them, and how you can gain access to them and their organizations. Our relationship mapping tool empowers you to discover new relationships, advance existing ones, and maximize every opportunity.

Relationship Science (RelSci) is a technology solutions company that helps individuals and organizations leverage their relationships for a competitive business advantage. The RelSci platform provides deep information about over 6 million influential decision makers - who they are and who they know, what you have in common with them, and how you can gain access to them and their organizations. Our relationship mapping tool empowers you to discover new relationships, advance existing ones, and maximize every opportunity.

Transactis transforms traditional paper billing and payment processing by enabling businesses of all sizes to replace paper bills, statements, invoices, payments and documents with more efficient digital alternatives. Transactis goes to market exclusively with resellers—financial institutions, technology companies, printers and business process outsourcers—to provide their customers with secure, configurable, white-label, industry-leading SaaS solutions. More than a technology provider to resellers, Transactis is a full-service business partner, delivering a broad and deep suite of sales, marketing, technical and operational support, empowering resellers to more successfully serve their clients. Transactis meets the strictest regulatory and compliance requirements including HIPAA, SSAE 16, PCI Level 1, and SOC 2. Transactis’ investors include ff Venture Capital, MacAndrews & Forbes, Metamorphic Ventures, Safeguard Scientifics, StarVest Partners, Capital One, Fifth Third Bank, PNC, TD Bank and Wells Fargo.

CircuLite is a cardiovascular device company that is transforming heart failure treatment with the development of minimally-invasive micro-pumps for long-term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient's native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients and their families. The company's proprietary micro-pump platform enables its PCS devices to be so small that they can be implanted superficially in a pacemaker-like pocket with endovascular or minimally-invasive surgical techniques.

SIGA is a pharmaceutical company specializing in the development of pharmaceutical solutions for some of the most lethal pathogens – variola (smallpox), Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures.

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

Viaken Systems is the premier full service ASP (Application Service Provider) for the life sciences, offering solutions for biotechnology, pharmaceutical, and agricultural companies. Viaken hosts third-party research informatics application solutions and e-commerce services in the areas of genome informatics, chem informatics, and pharmaco informatics at its tier one data center and delivers these services via the Internet. The company’s unique ASP platform enables companies of all sizes to utilize the same state-of-the-art research information technology (IT) as implemented by top-tier organizations. Viaken specializes in architecture design, application and database hosting, distributed access to high performance computing services, secure network management, and 24x7x365 system and application support. The company also designs, implements, and hosts custom solutions to meet any of its customers’ IT requirements.

Driven by a desire to solve a real problem exacerbated by the Internet, Dennis Buchheim and David Wadhwani founded iHarvest in September 1997. When they discovered that many Internet users shared their same frustration—losing valuable content after surfing the Web—they developed an application that revolutionized the way people interact with the Web. iHarvest One™, the first-generation Web harvester software, premiered in July 1999. A Microsoft® Internet Explorer plug-in, iHarvest One allowed users to save entire Web pages or clips on their hard disks, organize them alongside other files, and share them with others. iHarvest One recently won the PC Magazine Editors' Choice award for best Web Information Manager. The overwhelming response to iHarvest One led to the next-generation Web service, iHarvest™, in May 2000. The leading Web information management tool, iHarvest makes saving and organizing Web content easy and provides a reliable, accessible, and convenient improvement over bookmarks. iHarvest's new Web service fundamentally changes the way Internet users interact with the Web—it is an indispensable tool for navigation through personal collections of digital content. iHarvest members can "harvest" their favorite Web content effortlessly, and access this information anytime, anywhere. iHarvest's intuitive interface lets members save and organize their Web content for any number of uses: financial research, job searching, competitive analysis, shopping comparison, market research, travel planning, house hunting, and much more. Appealing to novice and experienced users alike, iHarvest provides a powerful and unique solution for both business and personal applications. iHarvest is a privately funded Internet software and applications company based in Redwood Shores, California. Its executive team, led by software industry veteran Rich Buchheim, has extensive technology experience from companies such as Oracle, Apple, Intergraph, Camex, Autodesk, Netscape, and Best Internet. Incorporated in 1998, the company closed its first round of major venture funding in April 2000 and is poised for growth that will enable iHarvest, its members, and its partners to leverage the enormous volume of information on the Web.

With the continued growth of the Internet, improved streaming technologies, and the arrival of inexpensive high-bandwidth connections to households and businesses across the United States, the market for network-centric video applications is ready to explode. This is setting the stage for video to take a bigger role online, becoming one of the driving forces in the development of the Internet. Javu Technologies has created JavuNetwork and JavuNetplay - ASP-enabling video creation and management applications, which will give business owners and consumers the opportunity to edit, enhance, and integrate the many benefits of video into their Internet experience. JavuNetwork is a Java-based, network-centric multimedia content management application that gives individuals the ability to do high-powered video, image and audio editing right from their desktops over the Internet. JavuNetplay further simplifies the online non-linear content creation process through easy-to-use templates, allowing users to build videos directly from within an internet browser. They believe there is an excellent opportunity to incorporate the JavuNetwork and JavuNetplay ASP digital media editing and management services with every ISP’s and ICP’s content offerings.

e7th is a B2B marketplace that enables its users to purchase and sell fashion and footwear products.

Digital Coupon Company mission is to enable merchants and portals to build more profitable relationships with consumers.